Mataró, Barcelona, Spain, and Düsseldorf, Germany, 09 September 2026 - Minoryx Therapeutics and Neuraxpharm Group (Neuraxpharm), announce that the last patient has been enrolled in the global Phase 3 clinical...
Chimerix Awarded BARDA Contract for Advanced Development of CMX001 as Medical Countermeasure Against Smallpox
News | 02. 16. 2011
Chimerix
Chimerix, Inc., a pharmaceutical company developing orally available antiviral therapeutics, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Chimerix’s broad spectrum antiviral drug candidate, CMX001, as a medical countermeasure in the event of a smallpox release.
